Mary Ann Liebert, Inc., publishers

Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and a risk for serious disease in liver transplant recipients. Molecular tests that can identify early protein markers produced by EBV may have value for diagnosing active infection.

Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site.

Concussion is a common disorder estimated to affect no fewer than 1.7-3.8 million people in the U.S. each year.

New, advanced techniques are needed that can mimic the normal blood supply that feeds natural bone to improve the viability and success of restorative procedures to replace damaged or diseased bone tissue using engineered constructs.

Human Gene Therapy is expanding its editorial coverage with the launch of Human Gene Therapy Clinical Development early next year.

Mary Ann Liebert, Inc., publishers and the editorial leadership of the peer-reviewed journal Stem Cells and Development congratulate Sir John Gurdon and Shinya Yamanaka on being awarded the Nobel Prize for Physiology or Medicine.

Many biotech observers maintain that the future of healthcare will largely be based on the field of personalized medicine, reports Genetic Engineering & Biotechnology News (GEN).

Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN).

According to the Centers for Disease Control and Prevention (CDC), 1 in 88 children in the U.S. has autism spectrum disorder (ASD), a broad group of neurodevelopmental disorders.

The use of RNA in nanotechnology applications is highly promising for many applications, including the development of new therapeutic compounds.